Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

985.00USD
27 Apr 2017
Change (% chg)

$45.00 (+4.79%)
Prev Close
$940.00
Open
$985.00
Day's High
$985.00
Day's Low
$985.00
Volume
4
Avg. Vol
23
52-wk High
$1,231.90
52-wk Low
$788.70

Latest Key Developments (Source: Significant Developments)

Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1
11:53am EDT 

April 27 (Reuters) - Bristol-Myers Squibb Co ::Employee workforce reductions were about 900 for quarter-ended March 31, across all regions for manufacturing, selling, research and development personnel - SEC filing.In Q1 2017, discontinued development of FS102 which was in Phase I development for treatment of breast and gastric cancer.Will not exercise its option to purchase F-Star Alpha which was previously consolidated by company as a variable interest entity.IPRD charge of $75 million was included in research and development expense and attributed to noncontrolling interest in Q1.  Full Article

Bristol-Myers CFO: potential for 2017 U.S. growth for Opdivo
11:48am EDT 

April 27 (Reuters) - Bristol-myers Squibb :Cfo says now believes "there is potential for Opdivo to grow in the U.S. this year," even with increased competition.Cfo says continues to expect international sales for opdivo to grow for the full year.  Full Article

Transgene and Bristol-Myers Squibb announce clinical research collaboration
Tuesday, 25 Apr 2017 01:33am EDT 

April 25 (Reuters) - Transgene Sa : :Co and Bristol-Myers Squibb announce clinical research collaboration to evaluate TG4010 with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer.Phase 2 clinical trial will explore potential of combining Transgene's TG4010, in conjunction with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo.Under terms of agreement, Transgene will be sponsor of trial. Bristol-Myers Squibb will provide Opdivo for use in study..  Full Article

Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer
Friday, 21 Apr 2017 02:06pm EDT 

April 21 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.CHMP opinion based on tumor response rate and duration of response demonstrated in phase 2 checkmate -275 trial.  Full Article

Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology
Monday, 17 Apr 2017 06:59am EDT 

April 17 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Nordic Bioscience announce collaboration for fibrosis biomarker technology.Collaboration to develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis.  Full Article

Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb
Thursday, 13 Apr 2017 07:00am EDT 

Biogen Inc : Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168 . Biogen Inc - Biogen will be responsible for full development and global commercialization of bms-986168 in ad and psp . Biogen Inc - to assume all remaining obligations to former stockholders of Ipierian, Inc related to Bristol-Myers Squibb's acquisition of company in 2014 . Biogen Inc - may pay up to $550 million in remaining milestones plus royalties including a near term $60 million milestone .Biogen Inc - announced an agreement to exclusively license BMS-986168 from Bristol-Myers Squibb.  Full Article

Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors
Tuesday, 11 Apr 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Apexigen, Inc. announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with APX005M in advanced solid tumors . Bristol-Myers - Study to evaluate potential of APX005M + Opdivo to activate antigen-presenting cells in tumor microenvironment to show anti-tumor activity . Bristol-Myers Squibb- Study to enroll second-line metastatic non-small cell lung cancer patients who have failed prior chemotherapy .Study to also enroll metastatic melanoma patients who have failed prior I-O therapy.  Full Article

FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer
Tuesday, 4 Apr 2017 04:15pm EDT 

Bristol-myers Squibb Co : U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb's application for Opdivo (nivolumab) in previously treated DMMR or MSI-H metastatic colorectal cancer .Bristol-Myers Squibb Co - FDA granted application priority review, and FDA action date is August 2, 2017.  Full Article

Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo
Friday, 24 Mar 2017 08:31am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy . Bristol-Myers Squibb Co - positive opinion based on overall survival benefit demonstrated in phase 3 checkmate -141 trial . Bristol-Myers Squibb Co- safety profile of opdivo in checkmate -141 was consistent with prior studies in other tumors .Bristol-Myers Squibb - CHMP recommendation will now be reviewed by European Commission.  Full Article

Heat Biologics reports positive results from mid-stage lung cancer trial
Tuesday, 21 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat Biologics reports positive interim phase 2 lung cancer results in patients treated with hs-110 in combination with a checkpoint inhibitor . Immune responses to hs-110 were observed in all 5 patients that exhibited tumor reductions .No tumor reductions were observed in patients that did not mount an immune response to hs-110.  Full Article

More From Around the Web

Photo

Bristol-Myers' cancer drug Opdivo fuels Wall Street beat

NEW YORK Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs.